Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Ask Michael Burke -- Ignore unavailable to you. Want to Upgrade?

To: Eggolas Moria who wrote (73146)	1/10/2000 11:49:00 AM
From: Michael Bakunin	Read Replies (2) \| Respond to of 132070

I agree with your basic thesis, but I have been trimming (and in some cases selling) my genomics holdings during their x00% pops over the last few weeks. I can't speak for all-caps MB, but I do recall his buying INCY under 20 a little while back, so it's likely he's been the beneficiary of the runups, too. Just today, two of my small-cap genomics companies are up 20% and 40% respectively. Biotech is the new internet, I guess. -mb

To: Eggolas Moria who wrote (73146)	1/10/2000 1:37:00 PM
From: Knighty Tin	Read Replies (1) \| Respond to of 132070

Gary, I am one of the original Genomics players, though I've never owned Celera. I did own Human Genome and Incyte and Gene and made great money with them. I have no doubt about the medical efficacy of genomic mapping. What I have a problem with is the obvious, how do you become a licensing one stop shop for something as common as the human body? I don't think the future problems will be medical. They are more likely to be legal. That being said, I like their chances. At lower prices, of course. <g>